Advertisement

Topics

Kite’s Axi-Cel CAR-T: No Adcomm, No Problem

11:13 EDT 11 Aug 2017 | Elsevier Business Intelligence

Next CAR-T in line at US FDA, Kite’s axicabtagene ciloleucel, looks headed toward an early approval with the agency confirm...

Original Article: Kite’s Axi-Cel CAR-T: No Adcomm, No Problem

NEXT ARTICLE

More From BioPortfolio on "Kite’s Axi-Cel CAR-T: No Adcomm, No Problem"

Quick Search
Advertisement